Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Nischal Ranganath; John C. O'Horo; Douglas W. Challener; Sidna Tulledge-Scheitel; Marsha L. Pike; Michael O'Brien; Raymund R. Razonable; Aditya Shah

doi:10.1093/cid/ciac481

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Nischal Ranganath, John C. O'Horo, Douglas W. Challener, Sidna Tulledge-Scheitel, Marsha L. Pike, Michael O'Brien, Raymund R. Razonable, Aditya Shah

Research output: Contribution to journal › Article › peer-review

Abstract

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

Original language	English (US)
Pages (from-to)	e537-e539
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	76
Issue number	3
DOIs	https://doi.org/10.1093/cid/ciac481
State	Published - Feb 8 2023

Keywords

COVID-19
paxlovid
rebound phenomenon
therapeutics

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciac481

Cite this

Ranganath, N., O'Horo, J. C., Challener, D. W., Tulledge-Scheitel, S., Pike, M. L., O'Brien, M., Razonable, R. R., & Shah, A. (2023). Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), e537-e539. https://doi.org/10.1093/cid/ciac481

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. / Ranganath, Nischal; O'Horo, John C.; Challener, Douglas W. et al.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, No. 3, 08.02.2023, p. e537-e539.

Research output: Contribution to journal › Article › peer-review

Ranganath, N, O'Horo, JC, Challener, DW, Tulledge-Scheitel, S, Pike, ML, O'Brien, M, Razonable, RR & Shah, A 2023, 'Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 76, no. 3, pp. e537-e539. https://doi.org/10.1093/cid/ciac481

@article{68dd537e4dbc47a2915a22f35d000607,

title = "Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons",

abstract = "In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.",

keywords = "COVID-19, paxlovid, rebound phenomenon, therapeutics",

author = "Nischal Ranganath and O'Horo, {John C.} and Challener, {Douglas W.} and Sidna Tulledge-Scheitel and Pike, {Marsha L.} and Michael O'Brien and Razonable, {Raymund R.} and Aditya Shah",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",

year = "2023",

month = feb,

day = "8",

doi = "10.1093/cid/ciac481",

language = "English (US)",

volume = "76",

pages = "e537--e539",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

AU - Ranganath, Nischal

AU - O'Horo, John C.

AU - Challener, Douglas W.

AU - Tulledge-Scheitel, Sidna

AU - Pike, Marsha L.

AU - O'Brien, Michael

AU - Razonable, Raymund R.

AU - Shah, Aditya

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2023/2/8

Y1 - 2023/2/8

N2 - In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

AB - In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

KW - COVID-19

KW - paxlovid

KW - rebound phenomenon

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85147723267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147723267&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac481

DO - 10.1093/cid/ciac481

M3 - Article

C2 - 35698452

AN - SCOPUS:85147723267

SN - 1058-4838

VL - 76

SP - e537-e539

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

ER -

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this